E-drug: Ketotifen
---------------------------------------------
Sometimes it is useful to carefully listen to "authorities". Avery's
Drug Treatment was recently re-edited and published by Speight and
Holford on behalf of the ADIS Press - all have a reputation of being
industry-friendly.
On Ketotifen I read page 1032: "Trials in adults have been disappointing
and, although more beneficial to children, absolute improvement in lung
function is usually no more than slight. This, together with the long
run-in period necessary and initial drowsiness, especially in older
children and adults, has resulted in a lack of widespread acceptance
of this agent".
The message seems loud and clear.
Leo Offerhaus
The Netherlands
lo@euronet.nl
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.